ATE307597T1 - Verwendung von peg-ifn-alpha und ribavirin zur behandlung chronischer hepatitis c - Google Patents

Verwendung von peg-ifn-alpha und ribavirin zur behandlung chronischer hepatitis c

Info

Publication number
ATE307597T1
ATE307597T1 AT99927804T AT99927804T ATE307597T1 AT E307597 T1 ATE307597 T1 AT E307597T1 AT 99927804 T AT99927804 T AT 99927804T AT 99927804 T AT99927804 T AT 99927804T AT E307597 T1 ATE307597 T1 AT E307597T1
Authority
AT
Austria
Prior art keywords
ribavirin
ifn
peg
alpha
chronic hepatitis
Prior art date
Application number
AT99927804T
Other languages
English (en)
Inventor
Friederike Zahm
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8232086&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE307597(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Application granted granted Critical
Publication of ATE307597T1 publication Critical patent/ATE307597T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/642—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a cytokine, e.g. IL2, chemokine, growth factors or interferons being the inactive part of the conjugate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
AT99927804T 1998-06-08 1999-05-29 Verwendung von peg-ifn-alpha und ribavirin zur behandlung chronischer hepatitis c ATE307597T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP98110433 1998-06-08
PCT/EP1999/003746 WO1999064016A1 (en) 1998-06-08 1999-05-29 Use of peg-ifn-alpha and ribavirin for the treatment of chronic hepatitis c

Publications (1)

Publication Number Publication Date
ATE307597T1 true ATE307597T1 (de) 2005-11-15

Family

ID=8232086

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99927804T ATE307597T1 (de) 1998-06-08 1999-05-29 Verwendung von peg-ifn-alpha und ribavirin zur behandlung chronischer hepatitis c

Country Status (34)

Country Link
US (3) US20030053986A1 (de)
EP (1) EP1087778B1 (de)
JP (2) JP3839667B2 (de)
KR (2) KR20050055053A (de)
CN (1) CN1170543C (de)
AR (1) AR019855A1 (de)
AT (1) ATE307597T1 (de)
AU (1) AU767131B2 (de)
BR (1) BR9911076A (de)
CA (1) CA2334267C (de)
CL (1) CL2010000828A1 (de)
CO (1) CO5050297A1 (de)
CZ (1) CZ298681B6 (de)
DE (1) DE69927971T2 (de)
DK (1) DK1087778T3 (de)
ES (1) ES2251196T3 (de)
HR (1) HRP20000808A2 (de)
HU (1) HU228218B1 (de)
ID (1) ID29285A (de)
IL (2) IL139786A0 (de)
MA (1) MA26641A1 (de)
MY (1) MY124091A (de)
NO (1) NO325598B1 (de)
NZ (1) NZ508249A (de)
PE (1) PE20000560A1 (de)
PL (1) PL192364B1 (de)
RS (1) RS50144B (de)
RU (1) RU2271217C2 (de)
SA (1) SA99200208B1 (de)
SI (1) SI1087778T1 (de)
TR (1) TR200003635T2 (de)
TW (1) TWI241913B (de)
WO (1) WO1999064016A1 (de)
ZA (1) ZA200006814B (de)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR200003635T2 (tr) * 1998-06-08 2001-04-20 F.Hoffmann-La Roche Ag Peg-IFN-ALFA ve ribavirinin kronik hepatit C tedavisinde kullanılması.
MY164523A (en) * 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
JP5230052B2 (ja) 2000-05-26 2013-07-10 イデニクス（ケイマン）リミテツド フラビウイルスおよびペスチウイルス治療のための方法および組成物
AU8353601A (en) * 2000-08-07 2002-02-18 Sciclone Pharmaceuticals Inc Treatment of hepatitis c with thymosin, interferon and ribavirin
US7208167B2 (en) 2000-08-07 2007-04-24 Sciclone Pharmaceuticals, Inc. Treatment of hepatitis C with thymosin and peptide combination therapy
US7179791B2 (en) * 2001-01-11 2007-02-20 Duke University Inhibiting GS-FDH to modulate NO bioactivity
WO2003026589A2 (en) 2001-09-28 2003-04-03 Idenix (Cayman) Limited Methods and compositions for treating hepatitis c virus using 4'-modified nucleosides
KR100480429B1 (ko) * 2001-12-04 2005-04-06 선바이오(주) 인터페론-알파와 폴리에틸렌글리콜 유도체의 배합체
US7608600B2 (en) 2002-06-28 2009-10-27 Idenix Pharmaceuticals, Inc. Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections
NZ537662A (en) 2002-06-28 2007-10-26 Idenix Cayman Ltd 2'-C-methyl-3'-O-L-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections
TW200500375A (en) 2002-06-28 2005-01-01 Idenix Cayman Ltd Modified 2' and 3'-nucleoside prodrugs for treating flaviviridae
AP2005003213A0 (en) 2002-06-28 2005-03-31 Univ Cagliari 2'-C-methyl-3'-O-L-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections.
US7824851B2 (en) 2002-11-15 2010-11-02 Idenix Pharmaceuticals, Inc. 2′-branched nucleosides and Flaviviridae mutation
MXPA05006230A (es) 2002-12-12 2005-09-20 Idenix Cayman Ltd Proceso para la produccion de nucleosidos ramificados-2'.
AU2003300434A1 (en) * 2002-12-23 2004-07-22 Idenix (Cayman) Limited Process for the production of 3'-nucleoside prodrugs
CN100503628C (zh) 2003-05-30 2009-06-24 法莫赛特股份有限公司 修饰的氟化核苷类似物
US8615282B2 (en) 2004-07-13 2013-12-24 Dexcom, Inc. Analyte sensor
AU2005256963A1 (en) * 2004-06-23 2006-01-05 Centre National De La Recherche Scientifique 5-aza-7-deazapurine derivatives for treating infections with flaviviridae
CN101023094B (zh) 2004-07-21 2011-05-18 法莫赛特股份有限公司 烷基取代的2-脱氧-2-氟代-d-呋喃核糖基嘧啶和嘌呤及其衍生物的制备
BRPI0515279A (pt) 2004-09-14 2008-07-15 Pharmasset Inc preparação de ribofuranosil pirimidinas e purinas 2'fluoro-2'-alquil- substituìdas ou outras opcionalmente substituìdas e seus derivados
EP2899277A1 (de) 2004-11-26 2015-07-29 Pieris AG Verbindung mit Affinität für das zytotoxische T-Lymphozyten-assoziierte Antigen (CTLA-4)
EP1917037A2 (de) * 2005-08-15 2008-05-07 F.Hoffmann-La Roche Ag Peg-ifn-alpha und ribavirin zur hbv-behandlung
US9201979B2 (en) * 2005-09-14 2015-12-01 Millennial Media, Inc. Syndication of a behavioral profile associated with an availability condition using a monetization platform
ES2422290T3 (es) * 2005-12-23 2013-09-10 Idenix Pharmaceuticals Inc Procedimiento para preparar un producto intermedio sintético para la preparación de nucleósidos ramificados
US7964580B2 (en) 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
TW200946541A (en) 2008-03-27 2009-11-16 Idenix Pharmaceuticals Inc Solid forms of an anti-HIV phosphoindole compound
CA2729322C (en) 2008-06-24 2020-05-26 Technische Universitaet Muenchen Muteins of hngal and related proteins with affinity for a given target
BRPI0918653A2 (pt) * 2008-09-17 2015-12-01 Boehringer Ingelheim Int combinação de inibidor de ns3 protese de hcv com interferon e ribavirina.
CA2748057C (en) 2008-12-23 2018-07-03 Pharmasset, Inc. Nucleoside phosphoramidates
US8551973B2 (en) 2008-12-23 2013-10-08 Gilead Pharmasset Llc Nucleoside analogs
EP2376515A1 (de) 2008-12-23 2011-10-19 Pharmasset, Inc. Synthese von purinnukleosiden
CN102458470B (zh) 2009-05-08 2016-01-20 赛生制药有限公司 作为疫苗增强剂的α胸腺素肽
US8618076B2 (en) 2009-05-20 2013-12-31 Gilead Pharmasset Llc Nucleoside phosphoramidates
TWI598358B (zh) 2009-05-20 2017-09-11 基利法瑪席特有限責任公司 核苷磷醯胺
BR112012002709A2 (pt) 2009-08-05 2019-04-30 Pieris Ag formulações de liberação controlada de muteínas de lipocalina
PH12012500827A1 (en) 2009-10-30 2013-01-07 Boehringer Ingelheim Int Dosage regimens for hcv combination therapy comprising bi201335, interferon alpha and ribavirin
EP3660510A3 (de) 2009-12-07 2020-07-08 Pieris Pharmaceuticals GmbH Muteine von humanem lipocalin 2 (lcn2, hngal) mit affinität für ein bestimmtes zielmolekül
CL2011000718A1 (es) 2010-03-31 2012-04-09 Gilead Pharmasset Llc Proceso para la preparacion de compuestos fosforados enantiomericos.
US8986951B2 (en) 2010-06-08 2015-03-24 Pieris Ag Tear lipocalin in muteins binding IL-4 R alpha
CA2808392C (en) 2010-08-16 2020-03-10 Pieris Pharmaceuticals Gmbh Binding proteins for hepcidin
EP2640740B1 (de) 2010-11-15 2017-03-15 Pieris Pharmaceuticals GmbH Muteine von menschlichem lipocalin 2 mit affinität für glypican-3 (gpc3)
PT3042910T (pt) 2010-11-30 2019-04-16 Gilead Pharmasset Llc 2'-espiro-nucleósidos para utilização na terapia da hepatite c
DK2646552T3 (en) 2010-12-02 2017-10-23 Pieris Pharmaceuticals Gmbh MUTEINES OF HUMAN LIPOCALIN 2 WITH AFFINITY FOR CTLA-4
AU2012308295B2 (en) 2011-09-16 2017-10-26 Gilead Sciences, Inc. Methods for treating HCV
US8889159B2 (en) 2011-11-29 2014-11-18 Gilead Pharmasset Llc Compositions and methods for treating hepatitis C virus
ES2863410T3 (es) 2011-12-13 2021-10-11 Pieris Pharmaceuticals Gmbh Métodos para prevenir o tratar ciertos trastornos mediante la inhibición de la unión de IL-4 y/o IL-13 a sus respectivos receptores.
WO2013174783A1 (en) 2012-05-23 2013-11-28 Pieris Ag Lipocalin muteins with binding-affinity for glypican-3 (gpc-3) and use of lipocalin muteins for target-specific delivery to cells expressing gpc-3
US20140039923A1 (en) * 2012-08-03 2014-02-06 AxelaCare Health Solutions, Inc. Computer program, method, and system for receiving and managing patient data gathered during patient treatments
MY172166A (en) 2013-01-31 2019-11-15 Gilead Pharmasset Llc Combination formulation of two antiviral compounds
EP2968490A1 (de) 2013-03-14 2016-01-20 Daiichi Sankyo Co., Ltd. Neuartige bindeproteine für pcsk9
CA2891557A1 (en) 2013-03-26 2014-05-22 Pieris Ag Novel specific-binding polypeptides and uses thereof
EP3650014B1 (de) 2013-08-27 2021-10-06 Gilead Pharmasset LLC Kombinationsformulierung von zwei antiviralen verbindungen
WO2015104406A2 (en) 2014-01-13 2015-07-16 Pieris Ag Multi-specific polypeptide useful for localized tumor immunomodulation
SG10201912019WA (en) 2014-05-22 2020-02-27 Pieris Pharmaceuticals Gmbh Novel specific-binding polypeptides and uses thereof
AU2016212087B2 (en) 2015-01-28 2019-11-07 Pieris Pharmaceuticals Gmbh Novel proteins specific for angiogenesis
BR112017017530A2 (pt) 2015-02-18 2018-04-17 Sanofi proteínas específicas para pioverdina e pioquelina
RU2736312C2 (ru) 2015-05-04 2020-11-13 ПИЕРИС ФАРМАСЬЮТИКАЛС ГмбХ Белки, специфичные в отношении cd137
AU2016258977C1 (en) 2015-05-04 2022-07-14 Pieris Pharmaceuticals Gmbh Anti-cancer fusion polypeptide
US10273275B2 (en) 2015-05-18 2019-04-30 Pieris Pharmaceuticals Gmbh Muteins of human lipocalin 2 with affinity for glypican-3 (GPC3) and methods of use thereof
AU2016262845B2 (en) 2015-05-18 2020-07-23 Pieris Pharmaceuticals Gmbh Anti-cancer fusion polypeptide
EP3115371A1 (de) 2015-07-07 2017-01-11 Sanofi Fusionsmoleküle
KR20180029238A (ko) 2015-07-15 2018-03-20 피어이스 파마슈티컬즈 게엠베하 Lag-3에 특이적인 신규 단백질
EA035586B1 (ru) 2015-11-30 2020-07-10 Пиерис Острелиа Пти Лтд. Новые антиангиогенные слитые белки
TW201725212A (zh) 2015-12-10 2017-07-16 第一三共股份有限公司 特異性於降鈣素基因相關胜肽的新穎蛋白
WO2018087108A1 (en) 2016-11-09 2018-05-17 Pieris Pharmaceuticals Gmbh Proteins specific for cd137
WO2018134274A1 (en) 2017-01-18 2018-07-26 Pieris Pharmaceuticals Gmbh Lipocalin muteins with binding affinity for lag-3
HRP20230590T2 (hr) 2018-07-31 2024-02-16 Pieris Pharmaceuticals Gmbh Novi fuzijski protein specifičan za cd137 i pd-l1
JP7476219B2 (ja) 2019-02-26 2024-04-30 ピエリス ファーマシューティカルズ ゲーエムベーハー Ｃｄ１３７およびｇｐｃ３に特異的な新規融合タンパク質
JP2023527908A (ja) 2020-06-05 2023-06-30 ピエリス ファーマシューティカルズ ゲーエムベーハー ４－１ｂｂをターゲティングする多量体免疫調節物質
EP4320141A1 (de) 2021-04-08 2024-02-14 Pieris Pharmaceuticals GmbH Neue für den bindegewebewachstumsfaktor (ctgf) spezifische lipocalinmuteine
WO2022243341A1 (en) 2021-05-18 2022-11-24 Pieris Pharmaceuticals Gmbh Lipocalin muteins with binding affinity for ox40
TW202428603A (zh) 2022-09-21 2024-07-16 美商思進公司 新穎的cd137及cd228特異性融合蛋白
WO2025175123A1 (en) 2024-02-16 2025-08-21 Seagen Inc. Methods of treating cancer using fusion proteins specific for cd137 and cd228

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4211771A (en) * 1971-06-01 1980-07-08 Robins Ronald K Treatment of human viral diseases with 1-B-D-ribofuranosyl-1,2,4-triazole-3-carboxamide
US4609546A (en) * 1982-06-24 1986-09-02 Japan Chemical Research Co., Ltd. Long-acting composition
US4681848A (en) * 1982-09-22 1987-07-21 Takeda Chemical Industries, Ltd. Novel peptide and use thereof
GB8430252D0 (en) * 1984-11-30 1985-01-09 Beecham Group Plc Compounds
US4766106A (en) * 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
DE3719046A1 (de) * 1987-06-06 1988-12-15 Basf Ag Verwendung von salzen von sulfonamidcarbonsaeuren als korrosionsinhibitoren in waessrigen systemen
US5122614A (en) * 1989-04-19 1992-06-16 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
US5238915A (en) * 1991-02-08 1993-08-24 Wakunaga Seiyaku K.K. Aromatic composition and method for controlling aroma
US5595732A (en) * 1991-03-25 1997-01-21 Hoffmann-La Roche Inc. Polyethylene-protein conjugates
US5281698A (en) * 1991-07-23 1994-01-25 Cetus Oncology Corporation Preparation of an activated polymer ester for protein conjugation
US5382657A (en) * 1992-08-26 1995-01-17 Hoffmann-La Roche Inc. Peg-interferon conjugates
US5359030A (en) * 1993-05-10 1994-10-25 Protein Delivery, Inc. Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same
US5643575A (en) * 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
US5919455A (en) * 1993-10-27 1999-07-06 Enzon, Inc. Non-antigenic branched polymer conjugates
HUT75533A (en) * 1993-11-10 1997-05-28 Schering Corp Improved interferon polymer conjugates
US5932462A (en) * 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
TW426523B (en) * 1995-04-06 2001-03-21 Hoffmann La Roche Interferon solution
US5695760A (en) * 1995-04-24 1997-12-09 Boehringer Inglehiem Pharmaceuticals, Inc. Modified anti-ICAM-1 antibodies and their use in the treatment of inflammation
US6387365B1 (en) * 1995-05-19 2002-05-14 Schering Corporation Combination therapy for chronic hepatitis C infection
CA2236591C (en) * 1995-11-02 2012-01-03 Schering Corporation Continuous low-dose cytokine infusion therapy
US5908621A (en) * 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
TW517067B (en) * 1996-05-31 2003-01-11 Hoffmann La Roche Interferon conjugates
US6172046B1 (en) * 1997-09-21 2001-01-09 Schering Corporation Combination therapy for eradicating detectable HCV-RNA in patients having chronic Hepatitis C infection
TR200003635T2 (tr) * 1998-06-08 2001-04-20 F.Hoffmann-La Roche Ag Peg-IFN-ALFA ve ribavirinin kronik hepatit C tedavisinde kullanılması.

Also Published As

Publication number Publication date
WO1999064016A1 (en) 1999-12-16
CN1305382A (zh) 2001-07-25
YU77000A (sh) 2003-08-29
SA99200208B1 (ar) 2006-08-15
CZ20004487A3 (en) 2001-06-13
HU228218B1 (en) 2013-02-28
AR019855A1 (es) 2002-03-20
NO325598B1 (no) 2008-06-23
US20070196385A1 (en) 2007-08-23
EP1087778A1 (de) 2001-04-04
MY124091A (en) 2006-06-30
PL192364B1 (pl) 2006-10-31
US20030053986A1 (en) 2003-03-20
SI1087778T1 (sl) 2006-02-28
HRP20000808A2 (en) 2001-10-31
CA2334267A1 (en) 1999-12-16
AU767131B2 (en) 2003-10-30
MA26641A1 (fr) 2004-12-20
TR200003635T2 (tr) 2001-04-20
HUP0102033A2 (hu) 2001-10-28
NO20006178D0 (no) 2000-12-05
JP2006160759A (ja) 2006-06-22
IL139786A (en) 2007-10-31
DE69927971D1 (de) 2005-12-01
RS50144B (sr) 2009-03-25
CO5050297A1 (es) 2001-06-27
DK1087778T3 (da) 2005-12-19
JP2002517451A (ja) 2002-06-18
RU2271217C2 (ru) 2006-03-10
PL344794A1 (en) 2001-11-19
CA2334267C (en) 2009-02-17
EP1087778B1 (de) 2005-10-26
JP3839667B2 (ja) 2006-11-01
KR20050055053A (ko) 2005-06-10
ES2251196T3 (es) 2006-04-16
TWI241913B (en) 2005-10-21
NZ508249A (en) 2003-02-28
CN1170543C (zh) 2004-10-13
KR20010052622A (ko) 2001-06-25
CZ298681B6 (cs) 2007-12-19
ZA200006814B (en) 2002-05-03
HUP0102033A3 (en) 2010-01-28
IL139786A0 (en) 2002-02-10
US20050031589A1 (en) 2005-02-10
ID29285A (id) 2001-08-16
CL2010000828A1 (es) 2011-02-11
HK1037981A1 (en) 2002-03-01
AU4503399A (en) 1999-12-30
DE69927971T2 (de) 2006-07-27
PE20000560A1 (es) 2000-07-05
BR9911076A (pt) 2001-02-20
NO20006178L (no) 2000-12-05

Similar Documents

Publication Publication Date Title
ATE307597T1 (de) Verwendung von peg-ifn-alpha und ribavirin zur behandlung chronischer hepatitis c
ATE365042T1 (de) Verwendung von morpholinol zur behandlung von sexuellen funktionsstörungen
ATE247987T1 (de) Behandlung zur beseitigung von gerüchen
ATE306481T1 (de) Pyrazolecarboxamide zur behandlung von fettleibigkeit und anderen erkrankungen
DE69925306D1 (de) Behandlung von kohlenwasserstoffgas
DE69703649D1 (de) Behandlung von deagglomerierten teilchen mit plasmaaktivierter spezies
DE69836915D1 (de) Mundpflegemittel zur behandlung von übelriechendem atem
ATE349428T1 (de) Prostaglandinagoniste und deren verwendung zur behandlung von knochenerkrankungen
ATE288748T1 (de) Verwendung von retigabin zur behandlung von neuropathischen schmerzen
ATE300597T1 (de) Behandlung von geweben
ATE253383T1 (de) Behandlung von in der luft enthaltenen mikroorganismen
DE69941566D1 (de) N-acetylhomotaurinate zur verwendung in der behandlung von hyperkinesie
DE69910782D1 (de) Behandlung von in der luft suspendierten allergenen
ATE338557T1 (de) Verwendung von cox2 inhibitoren zur behandlung von schizophrenia und des ticks
DE69930647D1 (de) Struktur-analoga von amin-basen und nucleosiden
DE69806801D1 (de) Galenische präparation zur prävention und behandlung von hepatokarzinomen
ATE395075T1 (de) Verwendung von il-18 inhibitoren zur behandlung und/oder prävention von atherosklerose
ATE218862T1 (de) Verwendung von 1-hydroxy-2-pyridonen zur behandlung von hautinfektionen
DE69734296D1 (de) Neue dikaffeoylchinasäurederivate und deren verwendung zur behandlung von hepatitis b
DE69840752D1 (de) Verwendung von coumarine zur behandlung von lebererkrankungen und pankreaserkrankungen
PL357674A1 (pl) Kompozycje i sposoby leczenia zaburzeń związanychz hiperlipidemią
ATE339955T1 (de) Verwendung von escitalopram zur behandlung von generalisierten angstzuständen
DE60027429D1 (de) Dihydrobenzodiazepinen und deren verwendung zur behandlung von dyslipidämien
ATE410181T1 (de) Verwendung von intereferon gamma zur behandlung von herzhypertrophie
ATE209891T1 (de) Verwendung von 1-hydroxy-2-pyridonen zur behandlung der seborrhoischen dermatitis

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1087778

Country of ref document: EP